Table 1.
Pathological and clinical characteristics of the inflammatory breast cancer (IBC) cohort
| IBC | |
|---|---|
| Total, n (%) | 156 (100) |
| Age (years) | |
| Median | 53 |
| Range | 23–84 |
| ≤50, n (%) | 63 (40.5) |
| >50, n (%) | 93 (59.5) |
| Sex, n (%) | |
| Female | 156 (100) |
| Male | 0 (0) |
| Stage, n (%) | |
| III | 120 (76.9) |
| IV | 36 (23.1) |
| ER status, n (%) | |
| Negative | 89 (57.1) |
| Positive | 67 (42.9) |
| PR status, n (%) | |
| Negative | 111 (71.2) |
| positive | 45 (28.8) |
| Her2 status, n (%) | |
| Negative | 113 (72.4) |
| Positive | 43 (27.6) |
| Subgroups, n (%) | |
| TNBC | 51 (32.7) |
| HR–/Her2+ | 33 (21.2) |
| HR+/Her2– | 62 (39.7) |
| HR+/Her2+ | 10 (6.4) |
| Distant metastases, n (%) | |
| Yes | 98 (62.8) |
| No | 58 (37.2) |
| SBR histological grade, n (%) | |
| I | 2 (1.3) |
| II | 63 (40.4) |
| III | 91 (58.3) |
ER estrogen receptor, Her2 human epidermal growth factor receptor 2, HR hormone receptor, PR progesterone receptor, SBR Scarf Bloom Richardson classification, TNBC triple-negative breast cancer